San Francisco-based ParcelBio has emerged from stealth mode with a USD 13 million seed financing raise to advance its APEXm (Amplified and Prolonged EXpression mRNA) platform, alongside an in vivo CAR-T program targeting autoimmune disease. The firm's tech is designed to tackle the durability constraints that have limited mRNA therapeutics beyond vaccines.
Breyer Capital led the round, with participation from General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital, ZAKA VC, and additional undisclosed investors. Y Combinator had previously backed the company through its Winter 2024 batch, providing an estimated USD 500,000 in pre-seed capital — bringing ParcelBio's total disclosed funding to approximately USD 13.5 million. The company said proceeds will support platform development, its lead autoimmune program, and additional programs in oncology and encoded protein therapeutics.
ParcelBio's core scientific premise is that conventional mRNA — even chemically modified variants such as those used in approved COVID-19 vaccines — degrades too rapidly inside cells to sustain the protein levels required for chronic disease indications. The APEXm platform addresses this by engineering novel RNA domains into the mRNA molecule itself, designed to recruit endogenous RNA-stabilizing machinery rather than relying on replication elements or circular RNA architectures. The company said preclinical data show significantly higher and more durable protein expression compared to a leading clinical mRNA design, with deeper target cell depletion observed in in vivo CAR-T models. ParcelBio is scheduled to present these data in an oral session at the American Society of Gene & Cell Therapy Annual Meeting on May 14, 2026.
The lead program targets pathogenic B cells across autoimmune diseases, with the stated goal of achieving deep B-cell depletion sufficient for durable, drug-free remission. The approach is designed to avoid ex vivo manufacturing and viral delivery — two significant barriers to scalability in current CAR-T development. The broader CAR-T in autoimmune disease field has attracted substantial attention following clinical reports of durable remission in refractory systemic lupus erythematosus and other conditions using ex vivo-manufactured CD19-directed CAR-T cells, including work published from groups in Germany. ParcelBio's in vivo mRNA-based approach, if validated, would represent a distinct manufacturing and delivery strategy relative to those precedents, though the company remains at a preclinical stage and cross-modality comparisons are premature.